Related Experiment Video
Updated: Aug 14, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
The regulation of N6-methyladenosine modification in PD-L1-induced anti-tumor immunity
Wei Yu1,2, Jinti Lin1,2, Tao Yu1,2
1Department of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Abstract:
There is growing evidence that programmed death ligand-1 (PD-L1) has exciting therapeutic efficacy in hematological malignancy and partial solid tumors. However, many patients still face failure with the treatment of immune checkpoint blockade because of PD-L1 expression regulation during transcription and post-transcription processes, including N6-methyladenosine (m6A). Similar to the epigenetic regulation in DNA and histones, recent research has revealed the essential regulation of m6A modification in RNA nuclear export, metabolism and translation. Recent studies have shown that m6A-induced PD-L1 expression emerges as one of the main reasons for the immunological alteration in this process and contributes to the failure of T cell-induced anti-tumor immunity. The results of preclinical studies demonstrate the potential of m6A-targeted therapy in combination with immune checkpoint blockade. The comprehensive expression of m6A-related genes also provided the possibility to indicate the prognosis and to optimize the treatment for patients of various cancer types. In this review, we focus on the m6A modification in PD-L1 mRNA as well as the regulation of PD-L1 expression in cancer cells and summarize its clinical value in anti-PD-L1 cancer immune therapy.
Insights
N6-methyladenosine (m6A) modification regulates programmed death ligand-1 (PD-L1) expression, impacting cancer immunotherapy. Targeting m6A shows promise for overcoming immune checkpoint blockade failure in various cancers.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Programmed death ligand-1 (PD-L1) is a key target in cancer immunotherapy, showing efficacy in hematological and solid tumors.
- Immune checkpoint blockade (ICB) therapy effectiveness is often limited by regulatory mechanisms of PD-L1 expression.
- N6-methyladenosine (m6A) modification is an emerging epigenetic regulator influencing RNA processes and gene expression.
Purpose of the Study:
- To review the role of m6A modification in regulating PD-L1 mRNA expression in cancer cells.
- To summarize the clinical implications of m6A-mediated PD-L1 regulation in anti-PD-L1 cancer immunotherapy.
- To explore the potential of m6A-targeted therapies in combination with ICB.
Main Methods:
- Literature review focusing on m6A modification, PD-L1 expression, and cancer immunology.
- Analysis of preclinical studies investigating m6A-targeted therapies and ICB.
- Examination of the role of m6A in RNA metabolism and PD-L1 regulation.
Main Results:
- m6A modification significantly impacts PD-L1 expression through transcriptional and post-transcriptional regulation.
- m6A-induced PD-L1 upregulation contributes to immune evasion by hindering T cell-mediated anti-tumor immunity.
- Preclinical data suggest m6A-targeted therapy can enhance ICB efficacy.
Conclusions:
- m6A modification is a critical factor in PD-L1 expression and a determinant of ICB response.
- Targeting m6A pathways offers a novel strategy to overcome resistance to PD-L1 blockade therapy.
- m6A-related gene expression may serve as a prognostic biomarker and guide treatment optimization in cancer immunotherapy.
Related Concept Videos
02:23Abnormal Proliferation
01:37Epigenetic Regulation
X-chromosome...
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....